Article
Endocrinology & Metabolism
Stefano Ciardullo, Gianluca Perseghin
Summary: The study found that the use of statins in patients with type 2 diabetes could reduce the risk of advanced liver fibrosis, with no significant interaction with steatosis. Therefore, specific randomized controlled trials with statins are recommended due to the lack of approved therapies for NAFLD-fibrosis.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2021)
Article
Pharmacology & Pharmacy
Michaela Gross, Skai W. Schwartz, Yuri V. Sebastiao, Amy Alman, Jason L. Salemi, Pragati Ghimire-Aryal, Philip Foulis
Summary: This study found a significant association between LDL reduction following statin use and new-onset diabetes mellitus in veterans. The association may be explained by potential lifestyle modifications individuals may make when prescribed a statin, independent of the statin usage.
ANNALS OF PHARMACOTHERAPY
(2023)
Article
Endocrinology & Metabolism
Longsheng Liao, Yamei Liu, Chunxiang Zheng, Yuan Xiang, Zhe Zhang, Xunjie Cheng, Yongping Bai
Summary: The study found that the use of statins in patients with type 2 diabetes receiving intensive glycemic therapy can lower the overall mortality rate, while the effects on cardiovascular mortality and primary outcomes are minimal.
DIABETES RESEARCH AND CLINICAL PRACTICE
(2021)
Article
Endocrinology & Metabolism
Walter Masson, Martin Lobo, Leandro Barbagelata, Juan P. Nogueira
Summary: The use of statins is associated with an increased risk of new-onset diabetes, particularly in studies with a high baseline risk of diabetes.
ACTA DIABETOLOGICA
(2023)
Article
Cardiac & Cardiovascular Systems
Morten Malmborg, Michelle D. S. Schmiegelow, Thomas Gerds, Morten Schou, Caroline Kistorp, Christian Torp-Pedersen, Gunnar Gislason
Summary: This study demonstrates that primary prevention with statins can reduce the risk of cardiovascular events or death in low-risk patients with T2D, with the greatest benefit seen in elderly patients and those with high adherence to statin treatment.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Cardiac & Cardiovascular Systems
Hesham Afify, Ubaldo Gonzalez-Morales, Abdo Asmar, Carlos A. Alvarez, Ishak A. Mansi
Summary: This study evaluated the effects of concurrent use of thiazide diuretics and statins on the progression of diabetes mellitus (DM), cardiovascular and renal outcomes, and death in patients with DM. The results showed that the concurrent use of thiazides and statins in patients with DM was associated with DM progression but with less kidney progression and cardiovascular outcomes and no difference in mortality. Clinicians should closely monitor DM control when thiazides and statins are used concurrently.
AMERICAN JOURNAL OF CARDIOLOGY
(2023)
Article
Endocrinology & Metabolism
Guoyi Yang, C. Mary Schooling
Summary: Mendelian randomization analysis showed that commonly used lipid modifiers, such as statins and ezetimibe, may increase the risk of type 2 diabetes, with a significant mediation effect by higher BMI. However, no significant associations were found between PCSK9 inhibitors and type 2 diabetes risk or BMI.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Medicine, General & Internal
Gil Lavie, Moshe Hoshen, Morton Leibowitz, Arriel Benis, Amichay Akriv, Ran Balicer, Orna Reges
Summary: This study found that the use of statins for primary prevention of cardiovascular disease in adults over 70 years old is beneficial and does not increase the risk of diabetes. However, for individuals under 70 years old, the risk-benefit ratio of statin therapy is less favorable compared to the older group.
AMERICAN JOURNAL OF MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Mario Luca Morieri, Valentina Perrone, Chiara Veronesi, Luca Degli Esposti, Margherita Andretta, Mario Plebani, Gian Paolo Fadini, Saula Vigili de Kreutzenberg, Angelo Avogaro
Summary: This study identified factors contributing to low achievement of LDL-cholesterol targets and underuse of lipid-lowering treatments in high- or very-high-cardiovascular risk patients. Gender, age, HDL-c, and triglyceride levels were found to delay statin prescriptions, indicating a need for modification to improve cardiovascular disease prevention. Late initiation of high-intensity treatments, especially in perceived low-risk patients, was highlighted as a key factor that needs to be addressed.
CARDIOVASCULAR DIABETOLOGY
(2021)
Article
Endocrinology & Metabolism
Mingyang Sun, Yuan Tao, Wan-Ming Chen, Szu-Yuan Wu, Jiaqiang Zhang
Summary: This study aimed to investigate the dose-dependent protective effects of statins, specific classes of statins, and different intensities of statin use on sepsis risk in patients with type 2 diabetes mellitus (T2DM). The results showed that statin use can reduce the incidence of sepsis and septic shock in T2DM patients. Specific classes of statins and higher doses of statins were associated with a reduced risk of sepsis.
DIABETOLOGY & METABOLIC SYNDROME
(2023)
Article
Cardiac & Cardiovascular Systems
Tobias Andersson, Jonatan Natman, Georgios Mourtzinis, Johan-Emil Bager, Kristina Bengtsson Bostrom, Stefan Franzen, Per Hjerpe
Summary: This Swedish study aimed to investigate the effect of statins on cardiovascular disease and mortality risks in hypertensive individuals without other cardiovascular diseases or diabetes. The results showed that primary prevention with statins was associated with a reduced risk of all-cause mortality, cardiovascular mortality, and lower risk of myocardial infarction (MI) in women.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Sami Erkinantti, Ari Hautakoski, Reijo Sund, Martti Arffman, Elina Urpilainen, Ulla Puistola, Esa Laara, Arja Jukkola, Peeter Karihtala
Summary: This study investigated the association between the use of metformin and statins and the prognosis of colorectal cancer in patients with type 2 diabetes. The results showed no significant association between metformin use and colorectal cancer mortality, but statin use was found to be inversely associated with mortality from colorectal cancer.
Review
Environmental Sciences
Leila Etemad, Zahra Salmasi, Seyedeh Alia Moosavian Kalat, Mohammad Moshiri, Javad Zamanian, Prashant Kesharwani, Amirhossein Sahebkar
Summary: Statins, the most widely used drugs for reducing blood cholesterol levels, have limitations in water solubility, bioavailability, and oral absorption. Nanotechnology-based formulations offer the potential to improve the effectiveness and bioavailability of statin therapy at low doses, reducing the risk of adverse effects. Nanocarriers provide tailored delivery platforms for statins, enhancing localized effects and reducing off-targeting and toxicity. This review explores the potential of nano-formulations in improving statin therapy.
ENVIRONMENTAL RESEARCH
(2023)
Article
Medicine, General & Internal
Meleeka Akbarpour, Divya Devineni, Yufan Gong, Nathan D. Wong
Summary: This study examined lipid levels and treatment status in patients with diabetes mellitus (DM), finding a lack of guideline-recommended use of high-intensity statins and inadequately controlled LDL-C among high-risk DM patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Anna Wesolowska, Hanna Winiarska, Jakub Owoc, Magdalena Borowska, Joanna Domagala, Przemyslaw Lukasz Mikolajczak, Saule Iskakova, Grzegorz Dworacki, Marzena Dworacka
Summary: The study showed that statins may have an antiangiogenic effect on PBMCs derived from patients with type 2 diabetes by reducing the secretion of proangiogenic factors like VEGF and MCP-1, while increasing the secretion of antiangiogenic factor Il-10. Additionally, the levels of VEGF, MCP-1, and Il-12 were higher in PBMCs cultured in a glucose-containing medium compared to a standard medium in each of the diabetic groups.
